Study Title
Randomized, Open, Positive Control Phase III Clinical Trial of Lutetium (177Lu) Oxodotreotide Injection Combined With Standard-dose Long-acting Octreotide Versus High-dose Long-acting Octreotide in the Treatment of Somatostatin Receptor-positive Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
Study Details
Description:
The study is being conducted to evaluate the efficacy, and safety of Lutetium (177Lu) Oxodotreotide Injection in Subjects With advanced gastrointestinal pancreatic neuroendocrine tumors.
Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Contacts:
Xueying Zhengxueying.zheng.xz17@hengrui.com
+0518-82342973
Government Study Link:
NCT05884255 - Click here to see study onClinicalTrials.gov